title: Cyclophosphamide as a first-line therapy in LGL leukemia.
authors.affiliation: Clinical Hematology Department-Rennes University Hospital, Rennes, France.
authors.forename: A
authors.initials: A
authors.lastname: Moignet
authors.affiliation: Penn State Hershey Cancer Institute, Pennsylvania State College of Medicine, Hershey, PA, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: Hasanali
authors.affiliation: Padua University School of Medicine, Department of Medicine, Hematology & Clinical Immunology Branch, Padua, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Zambello
authors.affiliation: Padua University School of Medicine, Department of Medicine, Hematology & Clinical Immunology Branch, Padua, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Pavan
authors.affiliation: Clinique de Cesson Sévigné-Rennes, Rennes, France.
authors.forename: B
authors.initials: B
authors.lastname: Bareau
authors.affiliation: Clinical Hematology Department, Hôpital Estaing, Clermont-Ferrand, France.
authors.forename: O
authors.initials: O
authors.lastname: Tournilhac
authors.affiliation: Hematology-Immunology and cell Therapy Department, Rennes University Hospital, Rennes, France.
authors.forename: M
authors.initials: M
authors.lastname: Roussel
authors.affiliation: 1] Hematology-Immunology and cell Therapy Department, Rennes University Hospital, Rennes, France [2] Rennes 1 University, Rennes, France.
authors.forename: T
authors.initials: T
authors.lastname: Fest
authors.affiliation: Penn State Hershey Cancer Institute, Pennsylvania State College of Medicine, Hershey, PA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Awwad
authors.affiliation: Penn State Hershey Cancer Institute, Pennsylvania State College of Medicine, Hershey, PA, USA.
authors.forename: K
authors.initials: K
authors.lastname: Baab
authors.affiliation: Padua University School of Medicine, Department of Medicine, Hematology & Clinical Immunology Branch, Padua, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Semenzato
authors.affiliation: 1] Clinical Hematology Department-Rennes University Hospital, Rennes, France [2] INSERM, CIC 0203, France [3] Rennes 1 University, Rennes, France.
authors.forename: R
authors.initials: R
authors.lastname: Houot
authors.affiliation: Penn State Hershey Cancer Institute, Pennsylvania State College of Medicine, Hershey, PA, USA.
authors.forename: T P
authors.initials: TP
authors.lastname: Loughran
authors.affiliation: 1] Clinical Hematology Department-Rennes University Hospital, Rennes, France [2] INSERM, CIC 0203, France [3] Rennes 1 University, Rennes, France.
authors.forename: T
authors.initials: T
authors.lastname: Lamy
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D054066:Leukemia, Large Granular Lymphocytic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide